Results of salvage radiotherapy alone in relapsed or refractory Hodgkin lymphoma
| Reference . | N . | OS . | Relapse-free survival . | Prognostic . |
|---|---|---|---|---|
| Josting et al65 | 100 | OS-5: 51% | FFTF-5: 26% | B symptoms |
| Advanced stage | ||||
| Poor performance status | ||||
| Campbell et al67 | 81 | OS-10: 46% | FFTF-10: 33% | B symptoms |
| Age > 50 years | ||||
| Extranodal disease | ||||
| < CR to previous chemotherapy | ||||
| Male sex | ||||
| Leigh et al68 | 28 | Median: 97 mo | Median RFS: 46 mo | Initial CR to chemotherapy |
| Pezner et al69 | 10 | OS-5: 60% | RFS-5: 30% | Disease-free interval < 1 y |
| Brada et al66 | 44 | OS-10: 40% | PFS-10: 23% | Age > 40 y |
| Extranodal disease | ||||
| Disease-free interval < 1 y | ||||
| MacMillan and Bessell70 | 11 | OS-10: 90% | DFS-10: 44% | NS |
| Uematsu et al71 | 28 | OS-7: 36% | RFS-7: 36% | NS |
| Reference . | N . | OS . | Relapse-free survival . | Prognostic . |
|---|---|---|---|---|
| Josting et al65 | 100 | OS-5: 51% | FFTF-5: 26% | B symptoms |
| Advanced stage | ||||
| Poor performance status | ||||
| Campbell et al67 | 81 | OS-10: 46% | FFTF-10: 33% | B symptoms |
| Age > 50 years | ||||
| Extranodal disease | ||||
| < CR to previous chemotherapy | ||||
| Male sex | ||||
| Leigh et al68 | 28 | Median: 97 mo | Median RFS: 46 mo | Initial CR to chemotherapy |
| Pezner et al69 | 10 | OS-5: 60% | RFS-5: 30% | Disease-free interval < 1 y |
| Brada et al66 | 44 | OS-10: 40% | PFS-10: 23% | Age > 40 y |
| Extranodal disease | ||||
| Disease-free interval < 1 y | ||||
| MacMillan and Bessell70 | 11 | OS-10: 90% | DFS-10: 44% | NS |
| Uematsu et al71 | 28 | OS-7: 36% | RFS-7: 36% | NS |
CR indicates complete remission; DFS-10, 10-year disease-free survival; FFTF-5, 5-year freedom from treatment failure; FFTF-10, 10-year freedom from treatment failure; NS, not stated; OS-5, 5-year overall survival; OS-10, 10-year overall survival; PFS-10, 10-year progression-free survival; RFS-5, 5-year relapse-free survival; and RFS-7, 7-year relapse-free survival.